rapid additional weight loss may increase risk of gallstones or nutritional deficiency if not monitored
Preclinical studies have shown pan-inhibition TGF- (monoclonal antibodies or small molecule inhibitor) to cause multiple organs damage, including cardiovascular toxicity (degeneration/necrosis and inflammation in the aortic root), hemorrhage in the GI tract and abdomen, and abnormal wound healing (Mitra et al
Ask HR: "Is our health plan self-funded?" and "Does our plan cover Wegovy for weight management?" Your employer controls the formulary, not Aetna
Tolomeo A, Zuccolotto G, Malvicini R, et al
If thyroid labs are optimized but symptoms such as weight gain, insulin resistance, or metabolic syndrome persist, a GLP-1 medication may be introduced to break through the plateau and support weight reduction
For localised injuries, injecting as close to the affected tissue as practical can improve outcomes significantly compared to a distant injection site
